within Pharmacolibrary.Drugs.ATC.J;

model J01DH04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 15.9 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,
    adminCount     = 1,
    Vd             = 0.016800000000000002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Doripenem is a carbapenem-class beta-lactam antibiotic used in the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and nosocomial pneumonia including ventilator-associated pneumonia. Approved for use in several countries, its marketing authorization has been withdrawn in some regions, but it is still available and used in others.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers following intravenous infusion.</p><h4>References</h4><ol><li><p>Zhanel, GG, et al., &amp; Karlowsky, JA (2007). Comparative review of the carbapenems. <i>Drugs</i> 67(7) 1027–1052. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200767070-00006&quot;>10.2165/00003495-200767070-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17488146/&quot;>https://pubmed.ncbi.nlm.nih.gov/17488146</a></p></li><li><p>Wang, Y, et al., &amp; Zhang, J (2022). Pharmacokinetics and Safety of Doripenem in Healthy Chinese Subjects and Monte Carlo Dosing Simulations. <i>Antibiotics (Basel, Switzerland)</i> 11(7) –. DOI:<a href=&quot;https://doi.org/10.3390/antibiotics11070958&quot;>10.3390/antibiotics11070958</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35884212/&quot;>https://pubmed.ncbi.nlm.nih.gov/35884212</a></p></li><li><p>Zhanel, GG, et al., &amp; Karlowsky, JA (2022). Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria. <i>Drugs</i> 82(5) 533–557. DOI:<a href=&quot;https://doi.org/10.1007/s40265-022-01688-1&quot;>10.1007/s40265-022-01688-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35294769/&quot;>https://pubmed.ncbi.nlm.nih.gov/35294769</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01DH04;
